Please assess the completion status of the following clinical trial:

Trial Title: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who had been diagnosed with iNHL that had progressed.~* Participants must have exhibited lack of CR or progressive disease (PR) or progression within 6 months after the last dose of a chemotherapy induction regimen or RIT.~* Participants must have had rituximab-refractory disease, defined as lack of CR or PR or PD within 6 months of last dose.~* Measurable disease with a lymph node or tumor mass ≥1.5 centimeters in at least one dimension by computed tomography (CT), positron emission tomography/CT or magnetic resonance imaging.~* Adequate renal and hepatic function.~Exclusion Criteria:~* Candidate for potentially curative therapies in the opinion of the investigator.~* Previous treatment with a PI3K inhibitor or Bruton's tyrosine kinase inhibitor.~* Prior history of allogeneic hematopoietic stem cell transplant.~* Prior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.~* Grade 3B FL and/or clinical evidence of transformation to a more aggressive subtype of lymphoma.~* Symptomatic central nervous system NHL.~* Ongoing systemic bacterial, fungal, or viral infections at the time of initiation of study treatment.~* Prior, current, or chronic hepatitis B or hepatitis C infection, positive result for hepatitis C virus antibodies, hepatitis B surface antigen, or hepatitis B core antibodies.~* History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duvelisib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).